Skip to main content
. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627
RECOMMENDATION 15
We recommend the use of plasma-derived C1 inhibitor as first-line long-term prophylaxis.
87% agreement, evidence level A